Equities research analysts expect Ascendis Pharma A/S (NASDAQ:ASND) to announce earnings per share of ($1.23) for the current quarter, Zacks reports. Three analysts have made estimates for Ascendis Pharma A/S’s earnings, with the highest EPS estimate coming in at ($0.79) and the lowest estimate coming in at ($1.41). Ascendis Pharma A/S reported earnings per share of ($1.22) in the same quarter last year, which would indicate a negative year-over-year growth rate of 0.8%. The business is expected to announce its next earnings results on Thursday, November 15th.
On average, analysts expect that Ascendis Pharma A/S will report full year earnings of ($4.22) per share for the current fiscal year, with EPS estimates ranging from ($4.83) to ($3.18). For the next financial year, analysts forecast that the business will report earnings of ($3.50) per share, with EPS estimates ranging from ($5.79) to ($0.28). Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that that provide coverage for Ascendis Pharma A/S.
Ascendis Pharma A/S (NASDAQ:ASND) last announced its earnings results on Wednesday, August 29th. The biotechnology company reported ($0.66) EPS for the quarter, topping the consensus estimate of ($1.03) by $0.37. The firm had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.16 million. Ascendis Pharma A/S had a negative net margin of 17,641.85% and a negative return on equity of 49.69%.
Several brokerages have commented on ASND. BidaskClub downgraded shares of Ascendis Pharma A/S from a “hold” rating to a “sell” rating in a report on Tuesday, October 9th. Stifel Nicolaus initiated coverage on shares of Ascendis Pharma A/S in a report on Tuesday, June 26th. They set a “buy” rating and a $85.00 target price on the stock. Canaccord Genuity initiated coverage on shares of Ascendis Pharma A/S in a report on Tuesday, August 7th. They issued a “buy” rating and a $81.00 price objective on the stock. ValuEngine upgraded shares of Ascendis Pharma A/S from a “buy” rating to a “strong-buy” rating in a report on Thursday, August 2nd. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Ascendis Pharma A/S from $79.00 to $81.00 and gave the company an “overweight” rating in a report on Thursday, August 30th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and nine have issued a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $77.25.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Quantbot Technologies LP bought a new position in shares of Ascendis Pharma A/S in the first quarter valued at $215,000. Kovack Advisors Inc. bought a new position in shares of Ascendis Pharma A/S in the first quarter valued at $218,000. Jane Street Group LLC bought a new position in shares of Ascendis Pharma A/S in the first quarter valued at $250,000. JPMorgan Chase & Co. bought a new position in shares of Ascendis Pharma A/S in the first quarter valued at $255,000. Finally, Atria Investments LLC grew its stake in shares of Ascendis Pharma A/S by 53.5% in the second quarter. Atria Investments LLC now owns 4,967 shares of the biotechnology company’s stock valued at $330,000 after buying an additional 1,731 shares in the last quarter. Institutional investors own 94.56% of the company’s stock.
ASND stock traded down $0.66 during mid-day trading on Wednesday, hitting $59.18. 4,332 shares of the company were exchanged, compared to its average volume of 145,549. The company has a market capitalization of $2.96 billion, a P/E ratio of -13.82 and a beta of 0.68. Ascendis Pharma A/S has a 1-year low of $31.56 and a 1-year high of $76.99.
Ascendis Pharma A/S Company Profile
Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.
Featured Story: How is the S&P 500 index different from the DJIA?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.